Amplitude Surgical (ENXTPA:AMPLI) - Share price, News & Analysis

AMPLI fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

AMPLI Stock Overview

Amplitude Surgical SA develops and markets products for orthopedic surgery.

Risk Analysis

Earnings have declined by 11.5% per year over past 5 years

Amplitude Surgical Competitors

Stryker

NYSE:SYK

US$88.8b

Zimmer Biomet Holdings

NYSE:ZBH

US$25.3b

Smith & Nephew

LSE:SN.

UK£11.4b

MicroPort Scientific

SEHK:853

HK$24.5b

Price History & Performance

Summary of all time highs, changes and price drops for Amplitude Surgical
Historical stock prices
Current Share Price	€2.77
52 Week High	€2.80
52 Week Low	€1.95
Beta	0.68
1 Month Change	2.21%
3 Month Change	8.63%
1 Year Change	27.06%
3 Year Change	14.46%
5 Year Change	-34.67%
Change since IPO	-44.60%

Shareholder Returns

	AMPLI	FR Medical Equipment	FR Market
7D	9.1%	4.4%	-1.1%
1Y	27.1%	-5.8%	-5.9%

Return vs Industry: AMPLI exceeded the French Medical Equipment industry which returned -5.8% over the past year.

Return vs Market: AMPLI exceeded the French Market which returned -5.9% over the past year.

Price Volatility

Is AMPLI's price volatile compared to industry and market?
AMPLI volatility
AMPLI Average Weekly Movement	4.0%
Medical Equipment Industry Average Movement	7.0%
Market Average Movement	5.9%
10% most volatile stocks in FR Market	10.0%
10% least volatile stocks in FR Market	3.4%

Stable Share Price: AMPLI is less volatile than 75% of French stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: AMPLI's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1997	453	Olivier Jallabert	https://www.amplitude-surgical.com

Amplitude Surgical SA develops and markets products for orthopedic surgery. The company provides a range of orthopedic products for primary and revision surgery aimed at treating pathologies of the hip, knee, and lower extremities primarily for foot and ankle surgery. It offers knee and hip prostheses and implants for the foot and ankle.

Amplitude Surgical Fundamentals Summary

How do Amplitude Surgical's earnings and revenue compare to its market cap?
AMPLI fundamental statistics
Market Cap	€126.65m
Earnings (TTM)	-€11.95m
Revenue (TTM)	€97.69m

1.4x

P/S Ratio

-11.1x

P/E Ratio

Is AMPLI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
AMPLI income statement (TTM)
Revenue	€97.69m
Cost of Revenue	€51.44m
Gross Profit	€46.25m
Other Expenses	€58.20m
Earnings	-€11.95m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Oct 19, 2022

Earnings per share (EPS)	-0.25
Gross Margin	47.35%
Net Profit Margin	-12.23%
Debt/Equity Ratio	240.3%

How did AMPLI perform over the long term?

See historical performance and comparison

Valuation

Is Amplitude Surgical undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

2.38x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AMPLI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AMPLI's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: AMPLI is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French Medical Equipment industry average.

PE vs Market: AMPLI is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AMPLI's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: AMPLI is overvalued based on its Price-To-Book Ratio (2.4x) compared to the FR Medical Equipment industry average (2.2x).

Future Growth

How is Amplitude Surgical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-5.2%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Amplitude Surgical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Amplitude Surgical performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-11.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: AMPLI is currently unprofitable.

Growing Profit Margin: AMPLI is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: AMPLI is unprofitable, and losses have increased over the past 5 years at a rate of 11.5% per year.

Accelerating Growth: Unable to compare AMPLI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AMPLI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (22.5%).

Return on Equity

High ROE: AMPLI has a negative Return on Equity (-23%), as it is currently unprofitable.

Financial Health

How is Amplitude Surgical's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: AMPLI's short term assets (€89.8M) exceed its short term liabilities (€38.0M).

Long Term Liabilities: AMPLI's short term assets (€89.8M) do not cover its long term liabilities (€168.8M).

Debt to Equity History and Analysis

Debt Level: AMPLI's net debt to equity ratio (195.1%) is considered high.

Reducing Debt: AMPLI's debt to equity ratio has increased from 92.8% to 240.3% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AMPLI has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: AMPLI has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 36.3% each year

Dividend

What is Amplitude Surgical current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate AMPLI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AMPLI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AMPLI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AMPLI's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as AMPLI has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure

CEO

Olivier Jallabert (53 yo)

25.33yrs

Tenure

€653,532

Compensation

Mr. Olivier Jallabert is a Founder of Amplitude Surgical SA and has been its Chief Executive Officer since June 10, 2015 and is Chairman of the Board. Mr. Jallabert is a Founder, Chief Executive Officer an...

CEO Compensation Analysis

Compensation vs Market: Olivier's total compensation ($USD700.16K) is above average for companies of similar size in the French market ($USD287.59K).

Compensation vs Earnings: Olivier's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: AMPLI's management team is considered experienced (3.8 years average tenure).

Board Members

Experienced Board: AMPLI's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/27 00:00
End of Day Share Price	2022/05/27 00:00
Earnings	2021/12/31
Annual Earnings	2021/06/30